Among these, 101 patients (28.1%) had FLT3-ITD mutations, whereas 259 patients (71.9%) had wild-type FLT3. The median age of patients with FLT3-ITD AML was 52 years (IQR 41-59) of compared to 51 years (IQR 36-61) for those with wild-type FLT3 AML (p=0.247). Here, FLT3 is linked to acute myeloid leukemia.